GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GB Sciences Inc (STU:18C) » Definitions » Shiller PE Ratio

GB Sciences (STU:18C) Shiller PE Ratio : (As of Mar. 04, 2025)


View and export this data going back to 2016. Start your Free Trial

What is GB Sciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


GB Sciences Shiller PE Ratio Historical Data

The historical data trend for GB Sciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GB Sciences Shiller PE Ratio Chart

GB Sciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GB Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GB Sciences's Shiller PE Ratio

For the Biotechnology subindustry, GB Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GB Sciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GB Sciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where GB Sciences's Shiller PE Ratio falls into.



GB Sciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

GB Sciences's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, GB Sciences's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0/133.0289*133.0289
=0.000

Current CPI (Sep. 2024) = 133.0289.

GB Sciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 -0.016 99.070 -0.021
201503 -0.120 99.621 -0.160
201506 -0.027 100.684 -0.036
201509 -0.053 100.392 -0.070
201512 -0.018 99.792 -0.024
201603 -0.027 100.470 -0.036
201606 -0.027 101.688 -0.035
201609 -0.028 101.861 -0.037
201612 -0.038 101.863 -0.050
201703 -0.019 102.862 -0.025
201706 -0.018 103.349 -0.023
201709 -0.017 104.136 -0.022
201712 -0.042 104.011 -0.054
201803 -0.057 105.290 -0.072
201806 -0.026 106.317 -0.033
201809 -0.043 106.507 -0.054
201812 -0.018 105.998 -0.023
201903 -0.018 107.251 -0.022
201906 -0.009 108.070 -0.011
201909 -0.009 108.329 -0.011
201912 0.004 108.420 0.005
202003 -0.036 108.902 -0.044
202006 -0.009 108.767 -0.011
202009 -0.002 109.815 -0.002
202012 -0.002 109.897 -0.002
202103 0.000 111.754 0.000
202106 -0.002 114.631 -0.002
202109 -0.001 115.734 -0.001
202112 0.009 117.630 0.010
202203 -0.011 121.301 -0.012
202206 -0.001 125.017 -0.001
202209 -0.001 125.227 -0.001
202212 -0.001 125.222 -0.001
202303 -0.006 127.348 -0.006
202306 -0.001 128.729 -0.001
202309 -0.002 129.860 -0.002
202312 0.000 129.419 0.000
202403 -0.001 131.776 -0.001
202406 -0.001 132.554 -0.001
202409 0.000 133.029 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GB Sciences  (STU:18C) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


GB Sciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of GB Sciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GB Sciences Business Description

Traded in Other Exchanges
Address
9205 W. Russell Road, Suite 240, Las vegas, NV, USA, 89148
GB Sciences Inc is active in the healthcare sector. The company is engaged in developing and utilizing technologies in plant biology, cultivation, and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for a range of ailments. The company's intellectual property covers various medical conditions, from which five drug development programs are in the preclinical stage of drug development including its formulations for Parkinson's disease (PD), chronic pain, cytokine release syndrome, depression, and cardiovascular therapeutic programs.

GB Sciences Headlines

No Headlines